Within‑woman hormonal changes: an underrecognized source of variability in drugs and diagnostics

Why timing inside a woman's body matters for medicine

Research and regulation increasingly recognize that sex matters in medicine, but most attention compares men and women at a single point in time. Less discussed — and less studied — is how a single person's biology changes over weeks, months and years: menstrual cycle phases, hormonal contraception, pregnancy and the transition to menopause can shift drug exposure, response and even diagnostic thresholds. These within‑woman changes are biologically plausible, sometimes measurable, but often absent from clinical guidance and trial reporting. The result is a patchwork of evidence, clinical uncertainty and missed opportunities to tailor care safely and equitably.

What the mechanistic and clinical literature says

Sex hormones regulate drug metabolism pathways. Reviews of preclinical and human data show estrogen and other reproductive‑stage signals affect ADME (absorption, distribution, metabolism and excretion) through changes in CYP enzymes, UGTs and transporters — for example, CYP3A4 activity is commonly reported as higher with estrogens, while other enzymes show variable sex or age patterns. These mechanisms create a plausible route by which menstrual cycling, exogenous hormones or menopause could alter drug concentrations and effects, but translational clinical data are patchy and heterogeneous ^[4] [12] ^[5].

Systematic human studies give a mixed picture. A 2025 meta‑analysis of antiseizure medications and lithium across menstrual phases found no consistent, large pharmacokinetic shifts for most drugs, though some agents (carbamazepine, phenytoin) showed measurable fluctuations in subgroups such as women with catamenial seizure exacerbations ^[2]. Conversely, narrative and review articles compiling menopause‑related data argue that falling estrogen around menopause can change clearance for drugs metabolized by pathways including CYP3A4, CYP1A2 and UGTs; the authors call for routine capture of menopausal status in trials because clinically meaningful within‑person changes are plausible and sometimes documented ^[3]. More broadly, comprehensive reviews emphasize that while sex differences in enzymes and transporters exist, their translation to dosing decisions depends on drug‑specific data we often lack ^[5] [12].

Diagnostics shift too: a concrete example

Biomarker thresholds can be sensitive to sex and age. High‑sensitivity cardiac troponin assays show lower 99th‑percentile values in women than men in population studies, and applying sex‑specific cutoffs changes who is classified as having myocardial injury ^[7]. Large clinical studies of rule‑out algorithms found trade‑offs: a uniform very low threshold safely identified many low‑risk patients including women, while sex‑specific 99th percentiles altered classification but had variable clinical impact depending on the algorithm and setting ^[6]. These findings illustrate a key point: biologic and assay differences can move diagnoses and downstream care decisions, but the net clinical benefit depends on how thresholds are used in practice ^[8].

Regulatory and reporting context

Regulators are paying more attention to sex and reproductive states. In 2025 the FDA released draft and final guidances urging sponsors to plan sex‑specific analyses and integrate sex data across product lifecycles; international workstreams (for example, an ICH concept on including pregnant and breastfeeding people in trials) similarly aim to close evidence gaps for hormonally distinct states ^{[9] [10] [11]}. Yet implementation lags: audits of NIH‑funded research show many papers fail to report sex‑disaggregated results or specify subject sex consistently, highlighting a policy‑to‑practice gap ^[1].

What this means for patients and clinicians today

• Recognize contexts where timing matters: conditions and medicines known to be hormone‑sensitive (certain antiseizure drugs, some psychotropics, drugs cleared by CYP3A4) and biomarkers like troponin are plausible candidates for attention to menstrual or menopausal state. Evidence quality varies by drug and outcome ^{[2] [3] [6]}.
• Document reproductive status: recording menstrual cycle phase, contraceptive use, pregnancy/lactation or menopausal status in the medical record and in studies is a low‑cost step that improves interpretation and future evidence building ^{[3] [9]}.
• Use available trial and label information: when product labels or trial reports document sex‑specific PK/PD, follow those recommendations; where labels are silent, exercise clinical judgment and consider monitoring drug levels or therapeutic effect more closely around known hormonal transitions.
• Communicate uncertainty with patients: explain when evidence is limited, what signs to watch for (loss of efficacy, side effects), and when to seek dose review — especially during pregnancy, after initiating or stopping hormonal contraception, or around menopause.

Research priorities and realistic next steps

To move beyond plausible mechanisms to practice‑changing evidence, the field needs targeted, drug‑specific studies that prospectively measure within‑woman hormonal state and drug exposure, adequately powered subgroup analyses, and routine reporting of sex and reproductive variables in trials and post‑market surveillance ^{[4] [5] [3]}. Regulatory guidances and international initiatives help set expectations, but auditing adherence and funding focused translational work will determine whether clinicians gain actionable guidance ^{[9] [11]}.

As of May 2026, the take‑away is pragmatic: biology within a single person changes over time, and those changes sometimes—but not always—affect medicines and diagnostics. Clinicians and patients should be aware, document reproductive context, and prioritize monitoring when starting or changing therapies during hormonal transitions while researchers and regulators continue to fill the evidence gaps.